Volume 12, Issue 5 (Sep-Oct 2018)
mljgoums 2018, 12(5): 16-22 |
Back to browse issues page
1- Department of Psychology, Kharazmi University, Tehran, Iran
2- Department of Psychology, Kharazmi University, Tehran, Iran , rynoury@yahoo.com
2- Department of Psychology, Kharazmi University, Tehran, Iran , rynoury@yahoo.com
Abstract: (10546 Views)
ABSTRACT
Background and Objectives: Cancer and its conventional treatments may bring about some psychological and health-related symptoms leading to unstable cortisol level. Since evidence has shown that mindfulness based approaches can be helpful to reduce cortisol level, we aimed at investigating the efficacy of mindfulness-based cognitive therapy (MBCT) on decreasing salivary cortisol level in the women with breast cancer.
Methods: in this one- group pretest posttest study, the women with early stage breast cancer were assessed to select eligible ones (N = 15). They were first trained for collecting salivary cortisol sample (before, after and follow-up) and then were asked to participate in MBCT, an eight-week session approach. Participants provided salivary samples in the morning (7: 30- 8:30), afternoon (1-3) and night (9-11). To measure cortisol, Cortisol Enzyme Immunoassay Kit was used. Analysis was performed on the data of 12 participants remained, using repeated measurement.
Results: the results of repeated measure ANOVA revealed that cortisol level of posttest (after 8-weeks of MBCT and follow-up period) in comparison with pretest was significantly reduced for morning and afternoon cortisol while it was not true for night cortisol. The post-treatment cortisol was not significantly correlated with age groups, education levels and socio-economic status using repeated measure ANCOVA.
Conclusion: Given that the women with breast cancer are at the high risk of psychological distresses and unstable cortisol level, we recommend mindfulness-based approaches esp. MBCT to health providers specifically those working with breast cancer patients.
Keywords: Mindfulness, MBCT, Cortisol , Salivary Cortisol, Breast cancer.
Background and Objectives: Cancer and its conventional treatments may bring about some psychological and health-related symptoms leading to unstable cortisol level. Since evidence has shown that mindfulness based approaches can be helpful to reduce cortisol level, we aimed at investigating the efficacy of mindfulness-based cognitive therapy (MBCT) on decreasing salivary cortisol level in the women with breast cancer.
Methods: in this one- group pretest posttest study, the women with early stage breast cancer were assessed to select eligible ones (N = 15). They were first trained for collecting salivary cortisol sample (before, after and follow-up) and then were asked to participate in MBCT, an eight-week session approach. Participants provided salivary samples in the morning (7: 30- 8:30), afternoon (1-3) and night (9-11). To measure cortisol, Cortisol Enzyme Immunoassay Kit was used. Analysis was performed on the data of 12 participants remained, using repeated measurement.
Results: the results of repeated measure ANOVA revealed that cortisol level of posttest (after 8-weeks of MBCT and follow-up period) in comparison with pretest was significantly reduced for morning and afternoon cortisol while it was not true for night cortisol. The post-treatment cortisol was not significantly correlated with age groups, education levels and socio-economic status using repeated measure ANCOVA.
Conclusion: Given that the women with breast cancer are at the high risk of psychological distresses and unstable cortisol level, we recommend mindfulness-based approaches esp. MBCT to health providers specifically those working with breast cancer patients.
Keywords: Mindfulness, MBCT, Cortisol , Salivary Cortisol, Breast cancer.
Research Article: Original Paper |
Received: 2018/08/13 | Accepted: 2018/08/13 | Published: 2018/08/13 | ePublished: 2018/08/13
Received: 2018/08/13 | Accepted: 2018/08/13 | Published: 2018/08/13 | ePublished: 2018/08/13
References
1. Hojati Z, Zamanzad B, Hashemzadeh M, Molaie R, Gholipour A. The FimH gene in uropathogenic Escherichia coli strains isolated from patients with urinary tract infection. Jundishapur J Microbiol. 2015; 8 (2): e17520. doi: 10.5812/jjm.17520. [DOI:10.5812/jjm.17520]
2. Tiba MR, Yano T, Leite DdS. Genotypic characterization of virulence factors in Escherichia coli strains from patients with cystitis. Rev Inst Med Trop Sao Paulo. 2008; 50(5): 255-60. [DOI:10.1590/S0036-46652008000500001]
3. Karimian A, Momtaz H, Madani M. Detection of uropathogenic Escherichia coli virulence factors in patients with urinary tract infections in Iran. Afr J Microbiol Res. 2012; 6(39): 6811-6. DOI: 10.5897/AJMR12.1462. [DOI:10.5897/AJMR12.1462]
4. Kulkarni R, Dhakal BK, Slechta ES, Kurtz Z, Mulvey MA, Thanassi DG. Roles of putative type II secretion and type IV pilus systems in the virulence of uropathogenic Escherichia coli. PLoS One. 2009;4(3):e4752. doi: 10.1371/journal.pone.0004752. [DOI:10.1371/journal.pone.0004752]
5. Saki A, Mirzaee M. Frequency of Fimbrial Virulence Genes (fim, pap, sfa) in Escherichia Coli Isolated from the Patients with Urinary Tract Infections. J Shahid Sadoughi Univ Med Sci. 2017; 24(11): 913-923.
6. Bien J, Sokolova O, Bozko P. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol. 2012; 2012:681473. [DOI:10.1155/2012/681473]
7. Rahdar M, Rashki A, Miri HR, Ghalehnoo MR. Detection of pap, sfa, afa, foc, and fim adhesin-encoding operons in uropathogenic Escherichia coli isolates collected from patients with urinary tract infection. Jundishapur J Microbiol. 2015; 8(8): e22647. doi: 10.5812/jjm.22647. [DOI:10.5812/jjm.22647]
8. Donnenberg MS, Welch RA. Virulence determinants of uropathogenic Escherichia coli: Urinary tract infections: molecular pathogenesis and clinical management. ASM Press, Washington, DC; 1996.
9. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev. 1991; 4(1): 80-128. [DOI:10.1128/CMR.4.1.80]
10. Tajbakhsh E, Ahmadi P, Abedpour-Dehkordi E, Arbab-Soleimani N, Khamesipour F. Biofilm formation, antimicrobial susceptibility, serogroups and virulence genes of uropathogenic E. coli isolated from clinical samples in Iran. Antimicrob Resist Infect Control. 2016; 5(1):11. [DOI:10.1186/s13756-016-0109-4]
11. Snyder JA, Lloyd AL, Lockatell CV, Johnson DE, Mobley HL. Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection. Infect Immun. 2006; 74(2): 1387-93. [DOI:10.1128/IAI.74.2.1387-1393.2006]
12. Knöbl T, Gomes T, Vieira M, Bottino J, Ferreira A. Detection of pap, sfa and fim adhesin-encoding operons in avian pathogenic Escherichia coli. Int J Appl Res Vet Med. 2004;2:135-141.
13. Ott M, Hoschützky H, Jann K, Van Die I, Hacker J. Gene clusters for S fimbrial adhesin (sfa) and F1C fimbriae (foc) of Escherichia coli: comparative aspects of structure and function. J Bacteriol. 1988;170(9):3983-90. [DOI:10.1128/jb.170.9.3983-3990.1988]
14. Le Bouguenec C, Archambaud M, Labigne A. Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol. 1992;30(5):1189-93.
15. Shetty A, Kumar S, Shekar M, Shetty A, Karunasagar I. Prevalence of adhesive genes among uropathogenic Escherichia coli strains isolated from patients with urinary tract infection in Mangalore. Indian J Med Microbiol. 2014;32(2):175. [DOI:10.4103/0255-0857.129812]
16. Dash SK, Chakraborty SP, Mandal D, Roy S. Isolation and characterization of multi drug resistant uropathogenic Escherichia coli from urine sample of urinary tract infected patients. Int J Life Sci Pharma Res. 2012;2:25-39.
17. Bagheri H, Ghaemi A, Aslani M, Mozafari N, Livani S, Dadgar T. The Prevalence of Enteroaggregative Escherichia coli in cases of Diarrhea in Gorgan, IRAN. Med Lab J. 2008;2(1):70.
18. Pusz P, Bok E, Mazurek J, Stosik M, Baldy-Chudzik K. Type 1 fimbriae in commensal Escherichia coli derived from healthy humans. Acta Biochim Pol. 2014;61(2):389-92.
19. Blanco M, Blanco J, Alonso M, Mora A, Balsalobre C, Munoa F, et al. Detection of pap, sfa and afa adhesin-encoding operons in uropathogenic Escherichia coli strains: relationship with expression of adhesins and production of toxins. Res Microbiol. 1997;148(9):745-55. [DOI:10.1016/S0923-2508(97)82450-3]
20. Nazemi A, Naderi M, Jafarpour M, Mirinargesi M, Sharifi SH. The Detection of Fimbrial Pathogenic Genes in E.coli Strains Isolated from Patients with Urinary Tract Infection. Med Lab J. 2010; 4(2):31–7.
21. Antão E-M, Wieler LH, Ewers C. Adhesive threads of extraintestinal pathogenic Escherichia coli. Gut Pathog. 2009;1(1):22. [DOI:10.1186/1757-4749-1-22]
22. Farshad S, Emamghorashi F. The prevalence of virulence genes of E. coli strains isolated from children with urinary tract infection. Saudi J Kidney Dis Transpl. 2009;20(4):613.
23. Garofalo CK, Hooton TM, Martin SM, Stamm WE, Palermo JJ, Gordon JI, et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun. 2007;75(1):52-60. [DOI:10.1128/IAI.01123-06]
24. Watts RE, Hancock V, Ong C-LY, Vejborg RM, Mabbett AN, Totsika M, et al. Escherichia coli isolates causing asymptomatic bacteriuria in catheterized and noncatheterized individuals possess similar virulence properties. J Clin Microbiol. 2010;48(7):2449-58. [DOI:10.1128/JCM.01611-09]
25. Silveira WDd, Benetti F, Lancellotti M, Ferreira A, Solferini VN, Brocchi M. Biological and genetic characteristics of uropathogenic Escherichia coli strains. Rev Inst Med Trop Sao Paulo. 2001;43(6):303-10. [DOI:10.1590/S0036-46652001000600001]
26. Dobrindt U, Blum-Oehler G, Hartsch T, Gottschalk G, Ron EZ, Fünfstück R, et al. S-Fimbria-Encoding Determinant sfa I Is Located on Pathogenicity Island III536 of UropathogenicEscherichia coli Strain 536. Infect Immun. 2001;69(7):4248-56. [DOI:10.1128/IAI.69.7.4248-4256.2001]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |